Asset Details
Do you wish to reserve the book?
Long-Term Vision Outcomes in Patients With DME and a Limited Early Visual Response to Ranibizumab in RIDE and RISE
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-Term Vision Outcomes in Patients With DME and a Limited Early Visual Response to Ranibizumab in RIDE and RISE
Do you wish to request the book?
Long-Term Vision Outcomes in Patients With DME and a Limited Early Visual Response to Ranibizumab in RIDE and RISE
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-Term Vision Outcomes in Patients With DME and a Limited Early Visual Response to Ranibizumab in RIDE and RISE
2020
Overview
BACKGROUND AND OBJECTIVE:To compare early and long-term visual responses to ranibizumab in patients with diabetic macular edema.
PATIENTS AND METHODS:Retrospective analysis of RIDE (NCT00473382) and RISE (NCT00473330). Vision outcomes over 36 months were compared between limited early gainers (gained ≤ 5 Early Treatment Diabetic Retinopathy Study [ETDRS] letters), early 1-line gainers (gained 6 to 9 ETDRS letters), and early 2-or-more-line gainers (gained ≥ 10 ETDRS letters) at Month 3.
RESULTS:Among 235 ranibizumab-treated patients, 42.6%, 20.0%, and 37.4% were limited early gainers, early 1-line gainers, and early 2-or-more-line gainers, respectively. At Month 36, 71.3% of limited early gainers achieved 6 to 9 and 10 or more ETDRS letter gains. Mean ETDRS letter scores at Month 36 were comparable between limited early gainers (67.8), early 1-line gainers (73.4), and early 2-or-more-line gainers (71.6).
CONCLUSION:Clinically meaningful vision outcomes were achieved with long-term ranibizumab treatment, irrespective of early visual acuity response.[Ophthalmic Surg Lasers Imaging Retina. 2020;51:210–218.]
Publisher
SLACK Incorporated,Slack, Inc,SLACK INCORPORATED
Subject
Angiogenesis Inhibitors - administration & dosage
/ Diabetes
/ Diabetic Retinopathy - complications
/ Diabetic Retinopathy - diagnosis
/ Diabetic Retinopathy - drug therapy
/ Dose-Response Relationship, Drug
/ Edema
/ Female
/ Humans
/ Lasers
/ Macular Edema - drug therapy
/ Male
/ Patients
/ Ranibizumab - administration & dosage
/ Tomography, Optical Coherence - methods
/ Vascular endothelial growth factor
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
/ Vision
